rly-4008
relay therapeutics
['rly-4008']
efficacy of rly-4008, a highly selective fgfr2 inhibitor in patients (pts) with an fgfr2-fusion or rearrangement (f/r), fgfr inhibitor (fgfri)-na v... | oncologypro 
Clinical Pharmacy Specialist - Early Drug Development- Memorial Sloan Kettering Cancer Center